Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All we know is that we're waiting for a decision by the FDA, one that is likely to be favorable. Everything else is idle conjecture and has no basis in reality. "hard to see a runup" ??? Maybe we'll have one tomorrow, maybe not. In either case it will take creative fantasy to extrapolate to some logic that indicates probabilities on the outcome.
The company can't sit on its butt, waiting to be acquired. That would be an invitation to a "low ball" offer. I like the full speed ahead preparations for selling the drug directly, and let some big Pharma make a good offer. If not, then the big payoff is delayed. Accepting delayed gratification is a sign of maturity (but I fear that gadflies are subject to episodic despondency, not the right temperament for investing in biotech).
Pluristem, a CLI company, or a Stem Cell Technology company ??
I believe it's the latter! As painful as this much anticipated result turned out to be, it's important to remember that CLI is (was) one specific instance of the general notion that (placental) stem cells have the potential to give us novel, high quality therapeutics.
This particular POC would have placed us on the map very convincingly and would have proven very profitable for the company and investors. The fact that it did not work out that way does not change the basic proposition (in terms of the technology).
Pluristem has accumulated an enormous amount of knowledge (production, distribution, regulatory) and a huge patent portfolio, not to mention a strong presence in the medical/scientific community. All of that is of significant advantage going forward.
The question remains on whether Pluristem can deliver a product with its remaining resources, and when. I'm optimistic on the continuing opportunities for the company. There is huge interest and scientific activity in this arena. My sense is that Pluristem is going to be able to capitalize on it's accumulated experience to come back. We do need just one success story to put us back on the right path. My hope is that the Covid effort will show that the cells are able to respond to the body's distress signals and thus prove the utility of the approach (even if Covid is "cured" by then).
I'm sticking around to see how it turns out, but whatever others decide, wishing all the best,
zzaatt.
Very good news on efficacy. It certainly shows the potential of the stem cell approach. Every success is further indication of the viability of the PLX platform in particular.
$12.90 (halleluhah !!!!!) NOT! GF, yes!
I like to give credit where it's due! EichKing, the political analyst (as opposed to Pluristem analyst) has made excellent points. The "woke" generation is vapid, moronic, ungrateful and is bent on destroying not only our own prosperity and freedom, but the hopes of oppressed people throughout the world.
As far as the nightmare Kamelah, she didn't break thru any glass ceiling. She washed out of her own party's primary and her "little black girl made it big" schtick is ludicrous garbage (just ask her well to do upper middle class professional parents).
Kamelah's other achievement is her membership in the wolf-pack that was mauling Judge Kavanaugh in one of the most obscene political spectacles ever performed in a Senate hearing.
I'm waiting for the brilliant young black woman Candice Owens to become president. My all time feminist hero is the Somali freedom fighter Ayaan Hirsi Ali, and the fact that liberals don't know who she is should shame all of them and especially P.Obama who invited Al Sharpie to the white house about a hundred times, but Ayaan who has a price on her head (too uppidy for the Islamists) was ignored. Tells you all you need to know about liberal concerns about racial justice and women's rights.
Mikems, sometimes I think that your posts have some gems of real wisdom (one does have to dig a bit to find it!). I don't know if C19 is our agent of destruction (probably not), but our descent is well documented by the fact that feeble, corrupt Biden was not crushed 10 to 1 by an outraged electorate, whose indignation at what the Left offered the country should have been manifest.
We can now look forward to our enemies (such as Iran, Russia, China) being embraced and our friends and fellow democracies (such as Israel, Hong Kong, Gr.Britain) being spat on, a la Obama. It will be a sad spectacle.
I'm looking forward to an imminent buyer's remorse and a huge midterm backlash against the left.
I think you'll find that the "Zelenko Protocol" is now the SOC treatment everywhere. The efficacy of these over the counter meds and vitamins has been emerging from physicians in the front lines of the Covid battle. Doctors share successful new approaches very fast.
This is very good news, BUT you will still need more radical remedies for the small percentage of patients whose age and comorbidities make them much higher risk for bad outcomes. That percentage is high enough that if Pluristem's cells work, there will be a substantial market space, enough to have a huge impact on the PPS.
I agree with you that it VERY unlikely that:
There is no "Mr. Market"! That's like the tooth fairy. If the GF is using a metaphor for market sentiment, it's too early in the game. Once we have FDA approval, once the impact of this drug becomes known, then we'll get the proper recognition AND pps.
We're certainly getting strong (albeit indirect) information that the Covid effort is ongoing and that Pluristem continues to get promising data.
To me this (esp. the steering committee) is a more valuable indicator of the state of things than corporate puffery.
Hi saud, yeah, it would (will ?? ) be nice. With AUPH we do have the advantage of a successful P3 in the bag, that does wonders for the probability of FDA approval.
As far as Pluristem, we have a number of shots at the target, we only need one to have a very substantial increase in PPS. Given the current valuation, I think a 5 to 10 bagger (to begin with) is easily possible. We do need that one clinical success!!!